Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Faron gets positive FDA feedback on bexmarilimab study plans
(Sharecast News) - Faron Pharmaceuticals announced positive feedback from the FDA regarding the clinical development plan for its drug candidate bexmarilimab, aimed at treating myelodysplastic syndrome (MDS), on Thursday. The AIM-traded firm said that in a formal meeting, the FDA acknowledged the challenges of conducting a randomised study with a comparator in the relapsed/refractory (r/r) setting, and instead proposed a confirmatory phase three study in frontline high-risk MDS (HR MDS).
That approach, Faron explained, would eliminate the need for a separate phase three study in r/r MDS.
It said the FDA's guidance was part of Project FrontRunner, an initiative designed to expedite the availability of promising new cancer treatments to a broader patient population.
The proposed phase three study would target a significantly larger patient group, potentially leading to faster approval and accelerating the sales forecast for bexmarilimab.
Faron said it initially planned to advance to a randomised registrational phase three study for r/r MDS using a combination of bexmarilimab and azacitidine against the investigator's choice of a hypomethylating agent (HMA).
However, given the encouraging efficacy and established safety profile of bexmarilimab, the FDA suggested moving directly to a registrational blinded randomised study in frontline HR MDS, comparing bexmarilimab plus azacitidine against placebo plus azacitidine.
The FDA indicated that the frontline study might not need to be substantially larger than the proposed r/r study due to the modest efficacy of single-agent azacitidine and current response rates with bexmarilimab.
Faron said the FDA also noted that the frontline study could fit within the context of Project FrontRunner, which encourages the development and approval of promising new cancer drugs for advanced diseases in earlier clinical settings.
Such a strategy would support accelerated approval in r/r settings based on response rates from a frontline trial, with full approval contingent on survival outcomes from the same study.
Subject to continued positive results, the feedback meant that a separate phase three study in r/r MDS would not be necessary.
Faron said its ongoing BEXMAB phase two study could serve as the registrational trial for r/r MDS, with interim response rate read-outs from the phase three frontline HR MDS study supporting accelerated approval.
Full approval would be based on survival data from the single phase three study.
"Faron is now adjusting its development plan accordingly," said chief executive officer Dr Juho Jalkanen.
"This is very positive feedback and exceeds our expectations.
"The FDA's proposal significantly reduces development costs and timelines to bring bexmarilimab therapy to all HR MDS patients."
Dr Jalkanen said the feedback underlined that the FDA saw the high unmet need in HR MDS - a condition for which new treatment options were urgently needed.
"The FDA's proposal has provided Faron with clear guidance on the path to approval that will confirm the highly encouraging results bexmarilimab has already obtained in overcoming resistance to azacitidine.
"We are extremely grateful for this feedback and will work hard to deliver on this recommendation."
At 1314 BST, shares in Faron Pharmaceuticals were up 29.29% at 128p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.